Yoda Therapeutics Begins Phase 2 Trial for MSA Treatment

Yoda Therapeutics Begins Phase 2 Trial for MSA Treatment

Yoda Therapeutics has dosed the first patient in its Phase 2 trial of YA-101 for Multiple System Atrophy, a rare neurodegenerative disorder.

Yoda Therapeutics Inc. has dosed the first patient in its Phase 2 trial of YA-101 for Multiple System Atrophy (MSA), announced in a press release. MSA is a rare and rapidly progressing neurodegenerative disorder that severely impacts motor functions and autonomic systems.

YA-101, a novel chemical entity, aims to treat neurodegenerative diseases by inhibiting neuroinflammation and enhancing neural plasticity. The Phase 2 trial will assess the safety, tolerability, pharmacokinetics, and efficacy of YA-101 in MSA patients across multiple sites in the United States and Taiwan. This trial follows the successful completion of Phase 1 trials in Australia, which focused on safety and tolerability in healthy volunteers.

The trial is designed as a randomized, double-blind, placebo-controlled study, targeting MSA patients with walking ability, including those requiring assistance. Comprehensive assessments will be conducted through clinical symptoms, biomarkers, and imaging.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following us on social media:

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more